Analysts expect Vistagen Therapeutics Inc (NASDAQ:VTGN) to announce ($0.07) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics posted earnings of ($0.24) per share in the same quarter last year, which suggests a positive year over year growth rate of 70.8%. The company is scheduled to report its next earnings report on Tuesday, February 11th.
On average, analysts expect that Vistagen Therapeutics will report full year earnings of ($0.40) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.35) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Vistagen Therapeutics.
Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01.
A number of analysts recently issued reports on the company. Maxim Group set a $4.00 price objective on Vistagen Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 15th. Chardan Capital reissued a “hold” rating and set a $0.70 price objective on shares of Vistagen Therapeutics in a report on Sunday, November 3rd. Finally, William Blair cut Vistagen Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $2.35.
VTGN traded up $0.02 during trading on Wednesday, reaching $0.44. 364,999 shares of the company were exchanged, compared to its average volume of 361,136. The company’s 50-day moving average is $0.85 and its two-hundred day moving average is $0.80. The company has a market cap of $20.75 million, a price-to-earnings ratio of -0.49 and a beta of -0.57. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 2.44. Vistagen Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.86.
A number of institutional investors and hedge funds have recently modified their holdings of VTGN. Wells Fargo & Company MN purchased a new stake in Vistagen Therapeutics during the 2nd quarter worth about $31,000. LPL Financial LLC bought a new position in Vistagen Therapeutics in the 2nd quarter worth about $27,000. HighTower Advisors LLC increased its stake in Vistagen Therapeutics by 326.3% in the 2nd quarter. HighTower Advisors LLC now owns 132,353 shares of the company’s stock worth $96,000 after acquiring an additional 101,308 shares during the last quarter. Vanguard Group Inc. increased its stake in Vistagen Therapeutics by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,196,181 shares of the company’s stock worth $868,000 after acquiring an additional 35,729 shares during the last quarter. Finally, D.A. Davidson & CO. increased its stake in Vistagen Therapeutics by 27.3% in the 3rd quarter. D.A. Davidson & CO. now owns 105,000 shares of the company’s stock worth $112,000 after acquiring an additional 22,500 shares during the last quarter. 8.61% of the stock is currently owned by institutional investors and hedge funds.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.